Effects of Eszopiclone on Sleep-dependent Learning in Schizophrenia
NCT ID: NCT00833547
Last Updated: 2014-09-09
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
25 participants
INTERVENTIONAL
2006-09-30
2012-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Eszopiclone on Sleep and Memory in Schizophrenia
NCT01641900
Randomized, Controlled, Double Blind Trial of Eszopiclone for Insomnia Associated With Schizophrenia
NCT00645944
The Effects of Nicotine on Cognition in Schizophrenia
NCT00383747
Effects of Auditory Stimulation on Sleep and Memory in Schizophrenia
NCT04783571
Modafinil Augmentation Therapy for Excessive Daytime Sleepiness and Negative Symptoms in Patients With Schizophrenia
NCT00546403
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Eszopiclone
3mg of eszopiclone on two consecutive nights
eszopiclone
3 mg of eszopiclone at bedtime on two consecutive nights
placebo
placebo capsule that looks identical to eszopiclone capsule on two consecutive nights
placebo
Placebo capsules looking identical to eszopiclone at bedtime on two consecutive nights
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
eszopiclone
3 mg of eszopiclone at bedtime on two consecutive nights
placebo
Placebo capsules looking identical to eszopiclone at bedtime on two consecutive nights
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Substance abuse or dependence within the past six months
* Other chronic medical conditions that affect sleep
* Pregnancy/breast feeding
* Hepatic impairment
* Treatment with metabolic inhibitors or inducers
18 Years
45 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sumitomo Pharma America, Inc.
INDUSTRY
Beth Israel Deaconess Medical Center
OTHER
Massachusetts General Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dara S. Manoach, PhD
Associate Professor of Psychology, Dept. of Psychiatry
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dara S. Manoach, PhD
Role: PRINCIPAL_INVESTIGATOR
Massachusetts General Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mass General Hospital
Boston, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Sepracor051
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.